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Abstract
Leishmaniasis is a vector-borne disease caused by Leishmania parasites, which cause a 
range of clinical manifestations in man. These are didactically classified into cutane-
ous leishmaniasis (CL), the most common form of the disease, and visceral leishmani-
asis (VL), the life-threatening form. There are so far no vaccines approved for humans. 
Conventional drugs pose limitations ranging from low efficacy and high cost to systemic 
toxicity. Low efficacy derives in part from difficult drug access to the parasites, which 
rides themselves inside macrophage phagosomes. This prompts to high dosage, with 
consequent increased toxicity. Difficult intracellular drug access can be overcome with 
nanomedicines such as biocompatible lipid and polymeric nanoparticles that can be 
phagocytosed by the infected macrophages. Besides cell membranes, appropriate drug 
nanostructuring may allow tissue barrier penetration and drug administration through 
higher compliance routes such as skin and intestine, in contrast to the usual intravenous 
and intramuscular routes. In general, CL and VL are both treated with toxic systemic 
injections, disregard of disease severity. This chapter will review and discuss studies 
with nanomedicines that have reached the market such as liposomal amphotericin B 
for intravenous administration, and innovative preclinical studies aiming at developing 
effective cutaneous and oral drugs with focus on CL.
Keywords: Leishmania, cutaneous leishmaniasis, chemotherapy, drug delivery 
systems, nanodrugs, liposomes, solid lipid nanoparticles, polymeric nanoparticles, 
nanoemulsions
1. Introduction
Leishmaniasis is a complex of neglected tropical diseases (NTDs) caused by intracellular 
protozoans of the genus Leishmania, transmitted to humans and other animals by the bite 
of infected female phlebotomine sand flies. Once in the vertebrate skin, the flagellated 
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promastigote forms are phagocytosed by local macrophages. Once inside macrophage 
phagolysosomes, the parasites survive enzyme digestion, transform into amastigote forms 
and multiply. Dermotropic parasite species causing cutaneous leishmaniasis (CL) remain 
in the skin, whereas viscerotropic species causing visceral leishmaniasis (VL) migrate to 
deeper macrophage-rich organs such as liver, spleen, and bone marrow.
Although not fatal as VL, CL is the most common form of leishmaniasis and a serious pub-
lic health problem. According to the World Health Organization (WHO) estimates, CL is 
endemic in 87 countries, with almost 200,000 new cases reported in 2015 [1]. From 2005 to 
2013, CL-associated morbidity increased by 175% of disability-adjusted life years (DALYs) 
[2]. The impact of CL may be much greater considering the high under-reported cases and 
estimation that one fourth of the world population (1.7 billion people) live in area at risk of 
infection [3]. In addition, inadequate disease control may promote the progression of CL to 
more morbid and undefined subforms, such as diffuse CL and mucosal leishmaniasis (ML).
In the great majority (>90%) of cases worldwide, CL is of the uncomplicated type, with 1–4 
localized skin ulcers, not larger than 3–4 cm diameter, with a raised border and central depres-
sion [4]. Even with localized manifestation, current treatment is normally based in the daily 
administration of intramuscular or intravenous injections with antimonials, pentamidine, or 
amphotericin B for 20–30 days. Besides limited to few drugs, and occurrence of drug resis-
tance, available CL treatment produces unacceptable systemic toxicity [5].
Ideally, CL chemotherapy as proposed by Drugs for Neglected Diseases initiative (DNDi) 
should be efficacious against all species, compatible in combination therapy, safe in pregnant 
and breastfeeding women, and administered by oral or topical route [6]. However, oral and 
topical therapies have shown limited efficacy.
The major challenge in CL treatment is the preferred intracellular parasite location in macro-
phage phagolysosomes. That hinders drug access, making treatment with conventional for-
mulations especially difficult [7].
Thus, the search for new drugs with different mechanisms of action and innovative forms of 
drug delivery systems appropriate for the effective treatment of CL is urgently needed. In that 
context, nanotechnology has emerged as an interesting strategy to increase drug potency and 
reduce toxicity.
Figure 1. Nanoparticle drug delivery to intracellular parasites. A drug-loaded lipid or polymeric nanoparticle (Np, 
yellow) reaches the Leishmania-infected macrophage (1). The Np is actively phagocytosed by the infected macrophage 
(2). The Np-containing phagolysosome fuses with the amastigote-containing parasitophorous vacuole (3). Drug is 
released from digested Np to kill amastigotes (4).
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Nanotechnology consists of the development of systems, structures, or devices in the nano-
metric scale, presenting at least one novel/superior characteristic or property over the origi-
nal [8]. The use of nanostructured particles for drug delivery is a promising strategy due to 
their versatility. Besides, they may: (i) protect the drug against physical, chemical, and/or 
enzymatic degradation, (ii) enhance the pharmacokinetic properties, and (iii) improve bio-
availability. They may also be functionalized for drug release at a specific site and thereby 
reduce systemic toxicity [7]. Furthermore, leishmaniasis is a particularly interesting disease 
to be treated with drug-loaded nanoparticles since the parasites almost exclusively infect the 
highly phagocytic macrophages. In this way, the infected cells of the skin (CL) or deep organs 
(VL) take up the nanoparticulated drug, which will reach the parasitophorous vacuole and 
act directly on the parasite (Figure 1). This allows the drug to reach an effective intracellular 
concentration, allowing dose and toxicity reduction. Particle uptake may be further increased 
with surface functionalization with receptor-binding ligands like mannose or mannan [9].
Interest in designing nanomedicines for CL has grown over the years, as seen by the steady 
increase in scientific publications. Several nanosystems, such as liposomes [10–20], solid 
lipid nanoparticles [21, 22], lipid complexes [23, 24], lipid-core nanocapsules [25], polymeric 
particles [26–31], inorganic nanoparticle [32–35], cyclodextrins complexes [36, 37], and drug 
nanoparticles [38] have been tested in vivo by different routes in experimental mouse and 
hamster models to improve CL treatment as summarized in Table 1. Of those, only liposomal 
Routes Drug Nanosystem Parasite Efficacy Ref
Parenteral Amphotericin B Chitosan and chondroitin 
sulfate nanoparticles
L. amazonensis Yes [26]
Amphotericin B Poloxamer 407-micelles L. amazonensis Yes [27]
Amphotericin B PLGA-DMSA nanoparticles L. amazonensis Yes [28]
Amphotericin B Liposome L. tropica No [10]
Amphotericin B Liposome (Ambisome®) L. major Yes [11]
Amphotericin B DSHemsPC-liposome L. major Yes [12]
Amphotericin B Nanodisks L. major Yes [23]
Amphotericin B PADRE-derivatized-
dendrimer complexed with 
liposome
L. major Yes [13]
Chalcone DMC PLA Nanoparticles L. amazonensis Yes [29]
Nanoselenium Inorganic nanoparticle L. major Yes [33]
Paromomycin Solid lipid nanoparticle L. major Yes [21]
Paromomycin Solid lipid nanoparticle L. tropica Yes [22]
Pentamidine Methacrylate nanoparticles L. major Yes [30]
Pentavalent 
antimonial
Nanohybrid hydrosols L. amazonensis Yes [38]
Sodium 
stibogluconate
Liposome L. mexicana /
L. major
Yes [14]
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amphotericin B has been approved for human leishmaniasis so far, but that is restricted to VL 
and the more severe mucosal form of CL. Additional studies and clinical trials are needed to 
validate the potential of those experimental nanomedicines in human CL.
Advances and challenges of nanotechnology use in leishmaniasis treatment, especially for 
VL, have been extensively reviewed recently [7, 39, 40]. Here, we attempted to identify some 
of the opportunities and challenges of using nanotechnology to improve CL treatment. For 
that, mainly in vivo studies were considered.
Routes Drug Nanosystem Parasite Efficacy Ref
Oral Quercetin Lipid-core nanocapsules L. amazonensis Yes [25]
Meglumine 
antimoniate
Beta-cyclodextrin L. amazonensis Yes [36]
Meglumine 
antimoniate
Polarity-sensitive 
nanocarrier
L. amazonensis Yes [24]
Topical Amphotericin B Liposome L. mexicana No [15]
Amphotericin B Gamma-cyclodextrin L. amazonensis Yes [37]
Chalcone CH8 Liposome L. amazonensis Yes [16]
Paromomycin Liposome L. major Yes [17]
Paromomycin Liposome L. major Yes [18]
Meglumine 
antimoniate
Liposome L. major Yes [19]
Nanosilver Inorganic nanoparticles L. major No [32]
[34]Nanosilver Inorganic nanoparticles L. major No
Intralesional Amphotericin B Liposome (Ambisome®) L. major No [11]
Chalcone CH8 PLGA microparticles L. amazonensis Yes [31]
Nanosilver Inorganic nanoparticles L. amazonensis Yes [35]
Meglumine 
antimoniate
Liposome L. major No [20]
Miltefosine Liposome L. major Yes [20]
Paromomycin Liposome L. major No [20]
Paromomycin Solid lipid nanoparticle L. tropica Yes [22]
Sodium 
stibogluconate
Liposome L. mexicana /
L. major
Yes [14]
Note: Chalcone DMC – 2’,6’-dihydroxy-4’-methoxychalcone; Chalcone CH8 – 3-nitro-2’-hydro-4’,6’-dimethoxychalcone; 
DMSA – dimercaptosuccinic acid; DSHemsPC – 1,2-distigmasterylhemi-succinoyl-sn-glycero-3-phosphocholine; 
PADRE – pan DR-binding epitope; PLA – poly(D,L-lactide); PLGA – poly(lactic-co-glycolic acid); UVB – ultraviolet B 
radiation.
Table 1. Experimental studies using nanosystems for CL treatment.
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2. Systemic therapies
2.1. Parenteral treatments
For more than 70 years, injectable pentavalent antimonials such as meglumine antimoniate 
(Glucantime®) and sodium stibogluconate (Pentostam®) have been the first-choice drugs in 
most countries. The paucity of new effective drugs in the market is due to lack of invest-
ment/economic interest for the discovery of therapeutic alternatives. The therapeutic regimen 
consists of intramuscular or intravenous daily injections for 20–30 days. The long period of 
treatment leads to the accumulation of antimony (Sb) in the tissues, producing myalgia, pan-
creatitis, pancytopenia, hepatic and cardiotoxicity [41]. Other limiting factors are drug resis-
tance and increased therapeutic failure [42]. In India, its use in VL has been contraindicated 
due to the appearance of resistant L. donovani strains [43].
In Sb-refractory cases, injectable pentamidine, amphotericin B or paromomycin are used. 
Pentamidine acts on the DNA synthesis of the parasite and has similar efficacy to antimonials, 
but also produces side effects such as hypoglycemia, diabetes, tachycardia, hypotension, 
nephrotoxicity and pain at the site of administration [44]. Like antimonials, cases of pentami-
dine resistance have been increasing, compromising their use in many endemic regions [45].
Amphotericin B is a polyene antibiotic mostly used in VL and in the disfiguring CL form, 
mucosal leishmaniasis, administered intravenously for 20 days, usually under hospital 
admission. This is the most efficacious antileishmanial drug, but it produces serious side 
effects due to its low solubility (nephrotoxicity), and secondary affinity not only for the para-
site ergosterol but also for the host cholesterol, causing hypokalemia and cardiotoxicity [5]. 
Formulations of amphotericin B in lipids have led to a marked improvement in their plasma 
solubility and bioavailability. Three lipid formulations are commercially available: unilamel-
lar liposomes (Ambisome®), lipid complex (Abelcet®) and colloidal cholesterol suspension 
(Amphocil®). Among these, Ambisome® has the highest plasma half-life, lowest toxicity, and 
highest efficacy against VL and CL models [46, 47]. In some countries, Ambisome® is already 
recommended as the first-choice drug for the treatment of VL and ML difficult cases. However, 
its high cost, the undefined optimum dosing regimen, toxicity, and the greater uptake of lipo-
somes by the liver make its widespread use in the treatment of CL unfeasible [48].
The interest in the administration of nanosystems by parenteral routes has been increased, 
mainly for VL, since they increase the drug bioavailability and depending on the charge, size 
and composition accumulate preferentially in organs such as liver. In addition, nanosystems 
can be conjugated to biological compounds, such as peptides, antibodies and mannose, favor-
ing their targeting to macrophages [9]. Thus, even with the dose reduction, the encapsulated 
drugs present greater efficacy and reduction of toxic effects. To date, most experimental stud-
ies are conducted parenterally that include chitosan and chondroitin sulfate nanoparticles, 
Poloxamer 407-micelles, PLGA-DMSA nanoparticles, PADRE-derivatized dendrimer com-
plexed with liposomes, PLA nanoparticles, solid lipid nanoparticles, methacrylate nanoparti-
cles, and liposomes (Table 1). Since amphotericin B is currently the most potent antileishmanial 
Nanomedicines for Cutaneous Leishmaniasis
http://dx.doi.org/10.5772/intechopen.75750
185
agent, most studies have used it in order to improve its specificity and reduce its adverse 
effects [10–12, 23, 26–28]. Despite the promising effects of nanomedicines obtained so far, 
Ambisome® remains the only nanomedicine approved for leishmaniasis parenteral treatment.
Another interesting strategy in the treatment of CL is the use of inorganic nanoparticles, such 
as nanoselenium, nanosilver and nanotitanium dioxide. Despite the promising efficacy of 
injected nanosilver [35] and nanoselenium [33] in CL models, the use of nanosilver by topical 
route was ineffective [32, 34], probably due to the lack of nanoparticle permeation through the 
infected skin, since those particles were directly active against culture parasites. Nanosilver 
may act directly on the Leishmania parasite by different mechanisms including: (i) increased 
cell cycle S phase length; (ii) inhibition of trypanothione/trypanothione reductase (TR) redox 
system; and (iii) cell necrosis [49].
The experimental parenteral routes are normally intravenous or intraperitoneal, the latter 
not applicable in clinical usage. An important issue to be considered when nanoparticles are 
intravenously injected is the possibility of thrombosis induction [50]. However, small and 
submicrometric they may be, larger aggregates can form and clog small veins [51]. Therefore, 
for safety reasons, intralesional, topical and oral routes should be preferable for CL treatment.
2.2. Oral treatment
The oral route is recommended for both CL and VL due to the ease of administration, high 
patient compliance, and versatility to increase drug bioavailability. However, systemic 
adverse effects cannot be precluded.
Miltefosine, a hexadecylphosphocholine previously used to treat cancer, is the only oral drug 
approved in VL treatment, with good cure rates in India, Nepal, and Bangladesh. However, 
its teratogenic potential, poor efficacy in patients coinfected with VL and human immunode-
ficiency virus and recently high rates of clinical failures have increasingly restricted its use in 
combination therapy [52]. Data on the efficacy of miltefosine in CL treatment are inconclusive, 
with a large variation depending on the parasite species and geographical area [53].
Another oral drug, allopurinol, an inhibitor of xanthine oxidase, has been explored since 
1982 when its activity was demonstrated in vitro. Despite the promising results in the oral 
treatment of CL in Asia, it does not appear to be as effective in Latin America [54]. The azoles 
act directly on the parasite, blocking the synthesis of ergosterol, and have good pharmacoki-
netic profile. However, clinical studies with fluconazole, ketoconazole, and itraconazole have 
shown controversial efficacy, suggesting that the effect is species-dependent [55–57].The main 
limiting factor for an oral drug is its low intestinal absorption. Nanosystems can overcome 
this problem by increasing aqueous solubility and epithelial barrier permeation. In addition, 
nanosystems can protect drugs from physical, chemical, and biological degradation. In this 
sense, a few studies have attempted to improve miltefosine and amphothericin B oral efficacy 
in VL models by encapsulation in nanosystems [58, 59]. For example, PLGA nanoparticles 
have been used to increase the oral bioavailability of the immunomodulator curcumin and 
the efficacy of miltefosine in hamsters infected with L. donovani [60]. However, only a few 
studies in the literature have used different nanosystems to increase drug efficacy in CL. In 
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L. amazonensis-infected BALB/c mice, nanoassemblies formed by two different complexes 
with N-Octanoyl-N-methylglucamide and β-cyclodextrin were used to increase intestinal 
permeability of a highly water-soluble meglumine antimoniate drug [24, 36]. More recently, 
quercetin, a poorly water-soluble plant flavonoid with promising antileishmanial activity 
[61], was successfully encapsulated in lipid-core poly-e-polycaprolactone (PCL) nanocap-
sules [25]. Nanoparticle encapsulation increased by more than 40-fold drug oral efficacy in 
BALB/c mice infected with L. amazonensis. The enhancing effect was possibly due to querce-
tin protection against extensive gastric and intestinal degradation [62]. Besides, PCL nano-
capsules were shown to be absorbed intact by mouse intestinal epithelia [63] and also taken 
up by M cells [64]. Whether or not absorbed quercetin-loaded particles reach the circulation 
[65] and Leishmania-infected skin macrophages remained to be determined.
3. Localized skin therapies
Local therapies are the ideal way to treat uncomplicated CL, as they avoid unnecessary sys-
temic side effects. This topic was subdivided in topical and intralesional treatments due to 
their different delivery approaches.
3.1. Topical treatment
Topical CL treatment may be provided with chemical drugs or physical methods, such as ther-
motherapy and cryotherapy. Thermotherapy is the application of high temperature (>50°C) at the 
center and border of each lesion, based on the inability of Leishmania to multiply at temperatures 
higher than 39°C. Its use has been restricted to the Old World, where 70% efficacy in repeated 
applications was shown to be similar to intramuscular or intralesional antimony [66]. Presently, 
thermotherapy is under clinical trial in Colombia in combination with a short course of oral milt-
efosine [67]. Cryotherapy is the application of liquid nitrogen (−195°C) in the center and border 
of the lesion once or twice a week for 6 weeks. This treatment has also shown ~70% efficacy 
[4]. Both therapies are well accepted by the patient, but the difficult access to the specific device 
(Thermomed), liquid nitrogen, and trained personnel for subjective applications limits their use.
Topical drug treatment of CL normally involves administration of drugs in the form of oint-
ments, creams or gels. These should be ideal for uncomplicated CL due to reduced hospital 
costs, since it can be auto-applied [44]. The most studied topical formulations are paromo-
mycin creams and gels. The low skin permeation of paromomycin requires association with 
strong permeants, such as methylbenzethonium chloride, urea and surfactant-associated 
gentamicin (WR-279396), which may produce local burn and skin irritation [68]. To circum-
vent that, some formulations have used the milder urea permeant; however, clinical efficacy 
remains variable depending on the parasite species and geographical area [4]. The results with 
the WR-279396 formulation are also conflicting, showing high efficacy in patients infected 
with L. panamensis in Panama [69], but not in patients infected with L. major in Tunisia [70].
Recently, DNDi supported a Phase Ib and II clinical study in Colombia evaluating the 
safety, pharmacokinetics, and efficacy of Anfoleish, a cream formulation containing 3% 
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 amphotericin B [71]. However, limited efficacy was found after topical application in patients 
infected with L. braziliensis and L. panamensis.
For an optimal topical formulation, the drug should be highly effective and have a high per-
meation through the skin, reaching the parasite in the deep dermal layer in effective concen-
trations. For the drug to successfully permeate the stratum corneum, it must possess adequate 
lipophilicity and a molecular size below 500 Da. The failure or partial success of the topical 
formulations of paromomycin (615 Da) and amphotericin B (924 Da) is directly related to the 
low permeability of these drugs through the skin, probably due to their high molecular size 
[72]. In addition, the typical morphology of CL ulcer with necrotic center and high borders 
influences the permeation of drugs. Although local inflammatory reaction may facilitate the 
permeation of more hydrophilic drugs [68], infected macrophages are located in the border 
of the lesions where epidermal thickening occurs, with hyperplasia and increased number of 
cell layers, which may hamper drug permeation.
Topical liposomes have emerged as an advantageous way to overlay this problem by increas-
ing drug skin permeation. In fact, some studies have shown the efficacy of liposomes loaded 
with paromomycin [17, 18] or meglumine antimoniate [19] in L. major-infected BALB/c mice, 
although even with the use of liposomes only 1.5% of antimoniate and a range of 4.8 to 15% 
of paromomycin were able to permeate through the skin. The use of liposomes was also 
shown to increase, the in vitro permeation and activity of amphotericin B in L. braziliensis 
promastigotes and intracellular amastigotes [73]. Nonetheless, in vivo another amphotericin 
B liposomal formulation did not show effectiveness in the topical treatment of CL caused by 
L. mexicana using ulcerated (BALB/c) and non-ulcerated (129SVE) experimental mice models 
[15]. On the other hand, in two different clinical studies conducted by the same research 
group in an endemic area for L. tropica and L. major at Ghaem Hospital in Iran, liposomes 
loading amphotericin B [74] and azithromycin [75] when administrated topically demon-
strated the same efficacy as intralesional meglumine antimoniate.
In the search for new active drugs for leishmaniasis, our group has been studying the chal-
cone CH8 (3-nitro-2’-hydro-4’,6’-dimethoxychalcone), a nitrosylated derivative of the plant-
derived chalcone (DMC – 2’,6’-dihydroxy-4’-methoxychalcone), which demonstrated a high 
selectivity index (SI = 143) and antileishmanial activity in vitro (IC
50
 = 0.7 μM) and in vivo 
against L. amazonensis [76]. In addition, the CH8 molecule exhibits physicochemical charac-
teristics favorable to encapsulation with high efficiency in different nanosystems such as lipo-
somes and polymeric particles. Indeed, CH8 loading into cationic liposomes interferes with 
the lipid structure rendering it more elastic, enhancing formulation permeation through the 
skin and increasing CH8 topical efficacy in L. amazonensis murine model [16].
Notwithstanding, the high phospholipid cost and liposomal instability hinder their use for 
CL. Thus, other nanosystems such as gamma-cyclodextrin have been studied for amphoteri-
cin B skin delivery to improve drug solubility and topical efficacy in L. amazonensis-infected 
golden hamsters [37]. Other interesting nanosystems are solid lipid nanoparticles (SLN), 
which can improve drug interaction with the stratum corneum facilitating permeation and 
improving the efficacy of the drug. The better activity of paromomycin entrapped in SLN was 
already described against L. major and L. tropica intracellular amastigotes [77]. Despite the 
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promising results found with the different nanosystems, additional in vivo studies are neces-
sary in order to develop an effective topical treatment for CL.
3.2. Intralesional treatments
Intralesional drug administration is an alternative local treatment for CL. This is especially 
appropriate for patients with uncomplicated localized CL—up to four lesions, each no more 
than 3 cm in diameter, as well as parenteral medication restrictions due to systemic toxic-
ity. Besides the lesser toxicity, local subcutaneous injections can accelerate clinical cure and 
reduce hospital costs as less injections are needed [4]. Pentavalent antimonials are the most 
used drugs, showing 68–100% efficacy in different clinical studies, depending on the size of 
the lesions [78–81]. Repeated injections are required due to the high solubility that favors 
rapid absorption into the circulation. Treatment generally consists of 1–5 injections around 
each lesion per day, twice a week. In addition to the pain inflicted, adverse effects like local 
hyperpigmentation and anaphylactic shock have been reported [82].
Amphotericin B has also been tested by intralesional route in Iran in patients refractory to anti-
mony therapy, leading to complete lesion remission in 61% of the cases [83]. Due to the nec-
rotizing effect of deoxycholate surfactant in amphotericin B formulation, the amount injected 
has to be as low as possible, reducing effectiveness. Thus, despite its high potential in CL, 
intralesional treatments need improvement, particularly as regards dose number reduction.
Intralesional drug-loaded nanoparticles have appeared as interesting drug delivery sys-
tems in CL due to direct drug delivery to the infected macrophages. However, for the for-
mulation to be effective, drug chemistry, nanosystem choice, and treatment schedule must 
be finely adjusted. Lipid systems such as SLN loaded with paromomycin have been tested 
intralesionally in L. tropica-infected BALB/c mice and shown increased drug efficacy by 
2-fold [22]. On the other hand, in another study comparing the efficacy of liposomal formula-
tions of Glucantime®, miltefosine and paromomycin in L. major-infected BALB/c mice, only 
liposomal miltefosine was shown to have therapeutic effect compared with control group 
[20]. Interestingly, intralesional Ambisome® was not effective in L. major-infected mice [11]. 
Additionally, intralesional Pentostam® liposomes were only effective if given at the time of 
infection with L. major or L. mexicana in TFW mice [14].
In this context, polymeric particles have emerged as an interesting strategy for CL intralesional 
and single-dose treatment. The advantage of this system is that particles smaller than 6 μM 
can be easily phagocytosed by infected macrophages releasing the drug directly into the target, 
whereas the larger microparticles form a depot slowly releasing the drug into the site, allowing at 
only one dose the drug to remain in the site of infection for the time needed for healing. The size 
of the microparticles and their polymer composition ensures retention of the drug in the lesion 
and determines its release time. In this way, adverse systemic effects are avoided and the effec-
tiveness of the drug is increased. Recently, the safety and efficacy of PLGA microparticles con-
taining chalcone CH8 in the intralesional treatment was demonstrated in L. amazonensis-infected 
BALB/c mice. Even a single subcutaneous injection with CH8-loaded particles was effective in 
controlling parasite growth, superior than three injections with the free drug or Glucantime®, 
demonstrating the promising use of these systems in local and single-dose treatment of CL [31].
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4. Conclusion
Since nanomedicines can be more efficiently taken up by the infected macrophages than free 
drugs, and also be designed to cross skin and epithelial barriers, they have emerged as prom-
ising strategies to allow novel topical and oral treatments for CL. Noteworthy is the possibil-
ity to treat the disease with a single local injection with biodegradable polymeric particles. 
Despite the promising results obtained with the different nanomedicines in pre-clinical stud-
ies, so far none has so far progressed to clinical trials in CL. Therefore, further efforts must be 
made in order to have them in the near future in the antileishmanial therapy arsenal.
Acknowledgements
A.J. Sousa-Batista is a recipient of Rio de Janeiro State Research Foundation—FAPERJ post-
doc grant # E-26/202.401/2017.
Conflict of interest
The authors have no conflict of interest to declare.
Author details
Ariane Sousa-Batista and Bartira Rossi-Bergmann*
*Address all correspondence to: bartira@biof.ufrj.br
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
References
[1] WHO. Global leishmaniasis update, 2006-2015: A turning point in leishmaniasis surveil-
lance. Weekly Epidemiological Record [Internet]. 2017;92:557-572. Available from: http://
www.who.int/wer/2017/wer9238/en/ [Accessed: 2017-11-16]
[2] WHO. Leishmaniasis in high-burden countries: An epidemiological update based on data 
reported in 2014. Weekly Epidemiological Record [Internet]. 2016;91:285-296. Available 
from: http://www.who.int/wer/2016/wer9122/en/ [Accessed: 2017-11-16]
[3] Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global distribution 
maps of the leishmaniases. eLife. 2014;3:1-21. DOI: 10.7554/eLife.02851.001
[4] Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opi-
nion on Pharmacotherapy. 2014;16:1-16. DOI: 10.1517/14656566.2015.973850
Leishmaniases as Re-emerging Diseases190
[5] Uliana SRB, Trinconi CT, Coelho AC. Chemotherapy of leishmaniasis: Present chal-
lenges. Parasitology. 2017;20:1-17. DOI:10.1017/S0031182016002523
[6] DNDi. DNDi’s Strategy for Cutaneous Leishmaniasis. 2017. Available from: https://www. 
dndi.org/diseases-projects/leishmaniasis/dndi-strategy-cl/ [Accessed: November 16, 
2017]
[7] Gutiérrez V, Seabra AB, Reguera RM, Khandare J, Calderón M. New approaches from 
nanomedicine for treating leishmaniasis. Chemical Society Reviews. 2016;45:152-168. 
DOI: 10.1039/C5CS00674K
[8] Bawa R, Melethil S, Simmons WJ, Harris D. Nanopharmaceuticals: Patenting issues and 
FDA regulatory challenges. The SciTech Lawyer. 2008;5:6-13
[9] Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: The 
phagocyte problem. Nano Today. 2015;10:487-510. DOI: 10.1016/j.nantod.2015.06.006
[10] Panosian CB, Barza M, Szoka F, Wyler DJ. Treatment of experimental cutaneous 
leishmaniasis with liposome-intercalated amphotericin B. Antimicrobial Agents and 
Chemotherapy. 1984;25:655-656
[11] Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutane-
ous leishmaniasis. Antimicrobial Agents and Chemotherapy. 1997;41:752-756
[12] Iman M, Huang Z, Alavizadeh SH, Szoka FC, Jaafari MR. Biodistribution and in vivo 
Antileishmanial activity of 1,2-distigmasterylhemisuccinoyl-sn-glycero-3-phosphocho-
line liposome-intercalated amphotericin B. Antimicrobial Agents and Chemotherapy. 
2017;61:1-16. DOI: 10.1128/AAC.02525-16
[13] Daftarian PM, Stone GW, Kovalski L, Kumar M, Vosoughi A, Urbieta M, et al. A tar-
geted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin 
B and enhances adaptive immunity in murine cutaneous leishmaniasis. The Journal of 
Infectious Diseases. 2013;208:1914-1922. DOI: 10.1093/infdis/jit378
[14] New RRC, Chance ML, Heath S. The treatment of experimental cutaneous leishmani-
asis with liposome-entrapped Pentostam. Parasitology. 1981;83:519-527. DOI: 10.1017/
S0031182000080501
[15] Varikuti S, Oghumu S, Saljoughian N, Pioso MS, Sedmak BE, Khamesipour A, et al. Topical 
treatment with nanoliposomal amphotericin B reduces early lesion growth but fails to 
induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania 
mexicana. Acta Tropica. 2017;173:102-108. DOI: 10.1016/j.actatropica.2017.06.004
[16] Rossi-Bergmann B, Falcao CAB, Zanchetta B, Bentley MVLB, Santana MHA. Performance 
of elastic liposomes for topical treatment of cutaneous Leishmaniasis. In: Beck R, 
Guterres S, Pohlmann A, editors. Nanocosmetics Nanomedicines New Approaches Ski. 
Care, Berlin, Heidelberg: Springer; 2011. pp. 181-196. DOI: 10.1007/978-3-642-19792-5_9
[17] Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA, et al. 
Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes 
for treatment of cutaneous leishmaniasis. Journal of Liposome Research. 2010;20:16-23
Nanomedicines for Cutaneous Leishmaniasis
http://dx.doi.org/10.5772/intechopen.75750
191
[18] Jaafari MR, Bavarsad N, Bazzaz BSF, Samiei A, Soroush D, Ghorbani S, et al. Effect of 
topical liposomes containing paromomycin sulfate in the course of Leishmania major 
infection in susceptible BALB/c mice. Antimicrobial Agents and Chemotherapy. 2009; 
53:2259-2265. DOI: 10.1128/AAC.01319-08
[19] Moosavian Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khashayarmanesh Z, Feizi 
E, et al. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the 
treatment of L. major lesion in BALB/c mice. Experimental Parasitology. 2014;143:5-10. 
DOI: 10.1016/j.exppara.2014.04.013
[20] Momeni A, Rasoolian M, Momeni A, Navaei A, Emami S, Shaker Z, et al. Development of 
liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmani-
asis. Journal of Liposome Research. 2013;23:134-144. DOI: 10.3109/08982104.2012.762519
[21] Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Badirzadeh A, Rafati S. Enhanced 
paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice 
model. Parasite Immunology. 2016;38:599-608. DOI: 10.1111/pim.12340
[22] Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Rafati S. Solid lipid nanopar-
ticle loaded with paromomycin: In vivo efficacy against Leishmania tropica infection in 
BALB/c mice model. Applied Microbiology and Biotechnology. 2016;100:7051-7060. 
DOI: 10.1007/s00253-016-7422-y
[23] Nelson KG, Bishop JV, Ryan RO, Titus R. Nanodisk-associated amphotericin B clears 
Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrobial Agents 
and Chemotherapy. 2006;50:1238-1244. DOI: 10.1128/AAC.50.4.1238-1244.2006
[24] Lanza JS, Fernandes FR, Corrêa-Júnior JD, Vilela JM, Magalhães-Paniago R, Ferreira LA, 
et al. Polarity-sensitive nanocarrier for oral delivery of Sb (V) and treatment of cuta-
neous leishmaniasis. International Journal of Nanomedicine. 2016;11:2305-2318. DOI: 
10.2147/IJN.S105952
[25] Sousa-Batista AJ, Poletto FS, Philipon CIMS, Guterres SS, Pohlmann AR, Rossi-Bergmann 
B. Lipid-core nanocapsules increase the oral efficacy of quercetin in cutaneous leishman-
iasis. Parasitology. 2017;144:1-6. DOI: 10.1017/S003118201700097X
[26] Ribeiro TG, Franca JR, Fuscaldi LL, Santos ML, Duarte MC, Lage PS, et al. An optimized 
nanoparticle delivery system based on chitosan and chondroitin sulfate molecules 
reduces the toxicity of amphotericin B and is effective in treating tegumentary leishman-
iasis. International Journal of Nanomedicine. 2014;9:5341-5353. DOI: 10.2147/IJN.S68966
[27] Mendonça DVC, Lage LMR, Lage DP, Chávez-Fumagalli MA, Ludolf F, Roatt BM, 
et al. Poloxamer 407 (Pluronic® F127)-based polymeric micelles for amphotericin B: In 
vitro biological activity, toxicity and in vivo therapeutic efficacy against murine teg-
umentary leishmaniasis. Experimental Parasitology. 2016;169:34-42. DOI: 10.1016/j.
exppara.2016.07.005
[28] de Carvalho RF, Ribeiro IF, Miranda-Vilela AL, de Souza Filho J, Martins OP, de Oliveira 
Cintra e Silva D, et al. Leishmanicidal activity of amphotericin B encapsulated in PLGA-
DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. Experimental 
Parasitology. 2013;135:217-222. DOI: 10.1016/j.exppara.2013.07.008
Leishmaniases as Re-emerging Diseases192
[29] Torres-Santos EC, Rodrigues JM, Moreira DL, Kaplan MAC, Rossi-Bergmann B. 
Improvement of in vitro and in vivo antileishmanial activities of 2′,6′- dihydroxy-4′-
methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles. Antimicrobial 
Agents and Chemotherapy. 1999;43:1776-1778
[30] Fusai T, Deniau M, Durand R, Bories C, Paul M, Rivollet D, et al. Action of pentamidine-
bound nanoparticles against Leishmania on an in vivo model. Parasite. 1994;1:319-324. 
DOI: 10.1051/parasite/1994014319
[31] Sousa-Batista AJ, Pacienza-Lima W, Arruda-Costa N, Falcão CAB, Rossi-Bergmann B. Depot 
subcutaneous injection with chalcone CH8-loaded PLGA microspheres aiming at a single-
dose treatment of cutaneous leishmaniasis. Antimicrobial Agents Chemotherapy. 2018;62: 
1-11. DOI: 10.1128/AAC.01822-17
[32] Mohebali M, Rezayat MM, Gilani K, Sarkar S, Akhoundi B, Esmaeili J, et al. Nanosilver in 
the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/
IR/75/ER): An in vitro and in vivo study. Daru. 2009;17:285-289
[33] Beheshti N, Soflaei S, Shakibaie M, Yazdi MH, Ghaffarifar F, Dalimi A, et al. Efficacy of 
biogenic selenium nanoparticles against Leishmania major: In vitro and in vivo studies. 
Journal of Trace Elements in Medicine and Biology. 2013;27:203-207. DOI: 10.1016/j.
jtemb.2012.11.002
[34] Nilforoushzadeh MA, Shirani-Bidabadi L, Zolfaghari-Baghbaderani A, Jafari R, Heidari-
Beni M, Siadat AH, et al. Topical effectiveness of different concentrations of nanosilver 
solution on Leishmania major lesions in Balb/c mice. Journal of Vector Borne Diseases. 
2012;49:249-253
[35] Rossi-Bergmann B, Pacienza-Lima W, Marcato PD, De Conti R, Duran N. Therapeutic 
potential of biogenic silver nanoparticles in murine cutaneous leishmaniasis. Journal of 
Nano Research. 2012;20:89-97
[36] Demicheli C, Ochoa R, da Silva JBB, Falcão CA, Rossi-Bergmann B, de Melo AL, et al. 
Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of 
leishmaniasis. Antimicrobial Agents and Chemotherapy. 2004;48:100-103. DOI: 10.1128/
AAC.48.1.100
[37] Ruiz HK, Serrano DR, Dea-Ayuela MA, Bilbao-Ramos PE, Bolás-Fernández F, Torrado 
JJ, et al. New amphotericin B-gamma cyclodextrin formulation for topical use with syn-
ergistic activity against diverse fungal species and Leishmania spp. International Journal 
of Pharmaceutics. 2014;473:148-157. DOI: 10.1016/j.ijpharm.2014.07.004
[38] Franco AMR, Grafova I, Soares FV, Gentile G, Wyrepkowski CDC, Bolson MA, et al. 
Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial 
drugs. International Journal of Nanomedicine. 2016;11:6771-6780. DOI: 10.2147/IJN.S121096
[39] Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmani-
asis: A review. Acta Tropica. 2017;172:86-90. DOI: 10.1016/j.actatropica.2017.04.029
[40] Bruni N, Stella B, Giraudo L, Della Pepa C, Gastaldi D, Dosio F. Nanostructured delivery 
systems with improved leishmanicidal activity: A critical review. International Journal 
of Nanomedicine. 2017;12:5289-5311. DOI: 10.2147/IJN.S140363
Nanomedicines for Cutaneous Leishmaniasis
http://dx.doi.org/10.5772/intechopen.75750
193
[41] Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: Current 
status and future directions. Molecular Biology International. 2011;2011:1-24. DOI: 
10.4061/2011/571242
[42] Castro MDM, Cossio A, Velasco C, Osorio L. Risk factors for therapeutic failure to meg-
lumine antimoniate and miltefosine in adults and children with cutaneous leishmani-
asis in Colombia: A cohort study. PLoS Neglected Tropical Diseases. 2017;11:1-14. DOI: 
10.1371/journal.pntd.0005515
[43] Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine & Inter-
national Health. 2001;6:849-854
[44] Iqbal H, Ishfaq M, Wahab A, Abbas MN, Ahmad I, Rehman A, et al. Therapeutic modali-
ties to combat leishmaniasis: A review. Asian Pacific Journal of Tropical Medicine. 2016; 
6:1-5. DOI:10.1016/S2222-1808(15)60975-6
[45] Basselin M, Denise H, Coombs GH, Barrett MP. Resistance to pentamidine in Leishmania 
mexicana involves exclusion of the drug from the mitochondrion. Antimicrobial Agents 
and Chemotherapy. 2002;46:3731-3738. DOI: 10.1128/AAC.46.12.3731
[46] Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formu-
lations against experimental visceral and cutaneous leishmaniasis. International Journal 
of Antimicrobial Agents. 2000;13:243-248. DOI: 10.1016/S0924-8579(99)00133-8
[47] De Almeida L, Fujimura AT, Del Cistia ML, Fonseca-Santos B, Imamura KB, Michels 
PAM, et al. Nanotechnological strategies for treatment of leishmaniasis – A review. 
Journal of Biomedical Nanotechnology. 2017;13:117-133. DOI: 10.1166/jbn.2017.2349
[48] Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al. Lipsosomal 
amphotericin B for treatment of cutaneous leishmaniasis. The American Journal of 
Tropical Medicine and Hygiene. 2010;83:1028-1033. DOI: 10.4269/ajtmh.2010.10-0171
[49] Zahir AA, Chauhan IS, Bagavan A, Kamaraj C, Elango G, Shankar J, et al. Green syn-
thesis of silver and titanium dioxide nanoparticles using Euphorbia prostrata extract 
shows shift from apoptosis to G0/G1 arrest followed by necrotic cell death in Leishmania 
donovani. Antimicrobial Agents and Chemotherapy. 2015;59:4782-4799. DOI: 10.1128/
AAC.00098-15
[50] Agallou M, Margaroni M, Athanasiou E, Toubanaki DK, Kontonikola K, Karidi K, 
et al. Identification of BALB/c immune markers correlated with a partial protection to 
Leishmania infantum after vaccination with a rationally designed multi-epitope cysteine 
protease a peptide-based nanovaccine. PLoS Neglected Tropical Diseases. 2017;11:1-27. 
DOI: 10.1371/journal.pntd.0005311
[51] Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R, Fröhlich E. The role of nano particle 
size in hemocompatibility. Toxicology. 2009;258:139-147. DOI: 10.1016/j.tox.2009.01.015
[52] Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, et al. Efficacy of miltefo-
sine in the treatment of visceral leishmaniasis in India after a decade of use. Clinical 
Infectious Diseases. 2012;55:543-550. DOI: 10.1093/cid/cis474
Leishmaniases as Re-emerging Diseases194
[53] Monge-Maillo B, López-Vélez R. Miltefosine for visceral and cutaneous leishmaniasis: 
Drug characteristics and evidence-based treatment recommendations. Clinical Infec-
tious Diseases. 2015;60:1398-1404. DOI: 10.1093/cid/civ004
[54] Vélez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. Inefficacy of allo-
purinol as monotherapy for Colombian cutaneous leishmaniasis: A randomized, con-
trolled trial. Annals of Internal Medicine. 1997;126:232-236
[55] Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of 
sodium stibogluconate (Pentostam) vs. ketoconazole for teating cutaneous leishmaniasis 
in Guatemala. The Journal of Infectious Diseases. 1992;165:528-534
[56] Alrajhi A, Ibrahim E, De Vol E, Khairat M, Faris R, Maguire J. Fluconazole for the treat-
ment of cutaneous leishmaniasis caused by Leishmania major. The New England Journal 
of Medicine. 2002;346:891-895. DOI: 10.1056/NEJM200208013470517
[57] Nassiri-Kashani M, Firooz A, Khamesipour A, Mojtahed F, Nilforoushzadeh M, Hejazi H, 
et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the 
treatment of cutaneous leishmaniasis. Journal of the European Academy of Dermatology 
and Venereology. 2005;19:80-83. DOI: 10.1111/j.1468-3083.2004.01133.x
[58] da Gama Bitencourt JJ, Pazin WM, Ito AS, Barioni MB, de Paula Pinto C, dos SMA, et al. 
Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing 
its hemolytic potential toward erythrocytes and its cytotoxic effect on macrophages. 
Biophysical Chemistry. 2016;217:20-31. DOI: 10.1016/j.bpc.2016.07.005
[59] Serrano DR, Lalatsa A. Oral amphotericin B: The journey from bench to market. Journal 
of Drug Delivery Science and Technology. 2017;42:75-83. DOI: 10.1016/j.jddst.2017.04.017
[60] Tiwari B, Pahuja R, Kumar P, Rath SK, Gupta KC, Goyal N. Nanotized curcumin and 
miltefosine: A potential combination for treatment of experimental visceral leishmania-
sis. Antimicrobial Agents and Chemotherapy. 2017;61:1-13. DOI: 10.1128/AAC.01169-16
[61] Muzitano MF, Falcão CAB, Cruz EA, Bergonzi MC, Bilia AR, Vincieri FF, et al. Oral 
metabolism and efficacy of Kalanchoe pinnata flavonoids in a murine model of cutane-
ous leishmaniasis. Planta Medica. 2009;75:307-311. DOI: 10.1055/s-0028-1088382
[62] Weiss-Angeli V, Poletto FS, De Marco SL, Salvador M, Da Silveira NP, Guterres SS, et al. 
Sustained antioxidant activity of quercetin-loaded lipid-core nanocapsules. Journal of 
Nanoscience and Nanotechnology. 2012;12:2874-2880. DOI: 10.1166/jnn.2012.5770
[63] Rodrigues SF, Fiel LA, Shimada AL, Pereira NR, Guterres SS, Pohlmann AR, et al. 
Lipid-core nanocapsules act as a drug shuttle through the blood brain barrier and 
reduce glioblastoma after intravenous or oral administration. Journal of Biomedical 
Nanotechnology. 2016;12:986-1000. DOI: 10.1166/jbn.2016.2215
[64] Lopes M, Abrahim B, Cabral L, Rodrigues C, Seiça R, de Baptista F, et al. Intestinal absorp-
tion of insulin nanoparticles: Contribution of M cells. Nanomedicine. 2014;10:1139-1151. 
DOI: 10.1016/j.nano.2014.02.014
Nanomedicines for Cutaneous Leishmaniasis
http://dx.doi.org/10.5772/intechopen.75750
195
[65] Li H, Chen M, Su Z, Sun M, Ping Q. Size-exclusive effect of nanostructured lipid carriers 
on oral drug delivery. International Journal of Pharmaceutics. 2016;511:524-537. DOI: 
10.1016/j.ijpharm.2016.07.049
[66] Cardona-Arias JA, Darío Vélez I, López-Carvajal L. Efficacy of thermotherapy to treat 
cutaneous leishmaniasis: A meta-analysis of controlled clinical trials. PLoS One. 2015; 
10:1-15. DOI: 10.1371/journal.pone.0122569
[67] DNDi D for ND initiative. Thermotherapy + A Short Course of Miltefosine for the Treat-
ment of Uncomplicated Cutaneous Leishmaniasis in the New World. ClinicalTrials.gov. 
2017. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02687971 [Accessed: 
January10, 2018]
[68] Van BK, Yardley V, Murdan S, Croft SL. Drug permeation and barrier damage in Leishmania- 
infected mouse skin. The Journal of Antimicrobial Chemotherapy. 2016;71:1578-1585. 
DOI: 10.1093/jac/dkw012
[69] Sosa N, Capitán Z, Nieto J, Nieto M, Calzada J, Paz H, et al. Randomized, double-blinded, 
phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis 
in Panama. The American Journal of Tropical Medicine and Hygiene. 2013;89:557-563. 
DOI: 10.4269/ajtmh.12-0736
[70] Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, et al. 
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. The 
New England Journal of Medicine. 2013;368:524-532. DOI: 10.1056/NEJMoa1202657
[71] DNDi D for ND initiative. Topical 3% Amphotericin B Cream for the Treatment of 
Cutaneous Leishmaniasis in Colombia (Anfoleish). ClinicalTrials.gov. 2017. Available 
from: https://clinicaltrials.gov/ct2/show/NCT01845727 [Accessed: January 10, 2018]
[72] Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical com-
pounds and drugs. Experimental Dermatology. 2000;9:165-169. DOI: 10.1034/j.1600- 
0625.2000.009003165.x
[73] Perez AP, Altube MJ, Schilrreff P, Apezteguia G, Celes FS, Zacchino S, et al. Topical 
amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, 
antifungal and antileishmanial activity in vitro. Colloids Surfaces B Biointerfaces. 2016; 
139:190-198. DOI: 10.1016/j.colsurfb.2015.12.003
[74] Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar Malekshah P, Moghiman T, Ashraf 
H, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine 
antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Journal of Para-
sitology Research. 2011;2011:1-5. DOI: 10.1155/2011/656523
[75] Rajabi O, Layegh P, Hashemzadeh S, Khoddami M. Topical liposomal azithromycin in 
the treatment of acute cutaneous leishmaniasis. Dermatologic Therapy. 2016;29:358-363. 
DOI: 10.1111/dth.12357
[76] Boeck P, Bandeira Falcão CA, Leal PC, Yunes RA, Filho VC, Torres-Santos EC, et al. 
Synthesis of chalcone analogues with increased antileishmanial activity. Bioorganic & 
Medicinal Chemistry. 2006;14:1538-1545. DOI: 10.1016/j.bmc.2005.10.005
Leishmaniases as Re-emerging Diseases196
[77] Kharaji MH, Doroud D, Taheri T, Rafati S. Drug targeting to macrophages with solid 
lipid nanoparticles harboring paromomycin: An in vitro evaluation against L. major and 
L. tropica. AAPS PharmSciTech. 2016;17:1110-1119. DOI: 10.1208/s12249-015-0439-1
[78] Sharquie KE, Al-Talib K, Chu A. Intralesional therapy of cutaneous leishmaniasis with 
sodium stibogluconate antimony. The British Journal of Dermatology. 1988;119:53-57
[79] Tallab TM, K a B, Mirdad S, Johargi H, Mourad MM, Ibrahim K, et al. Cutaneous leish-
maniasis: Schedules for intralesional treatment with sodium stibogluconate. Interna-
tional Journal of Dermatology. 1996;35:594-597
[80] Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional ther-
apy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, 
Brazil – An area of Leishmania (V.) braziliensis transmission. International Journal of Der-
matology. 1997;36:463-468
[81] Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, et al. Intralesional 
antimony for single lesions of Bolivian cutaneous leishmaniasis. Clinical Infectious 
Diseases. 2013;56:1255-1260. DOI: 10.1093/cid/cit049
[82] Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A. Adverse 
effects of intralesional meglumine antimoniate and its influence on clinical labora-
tory parameters in the treatment of cutaneous leishmaniasis. International Journal of 
Dermatology. 2012;51:1221-1225. DOI: 10.1111/j.1365-4632.2012.05460.x
[83] Goyonlo VM, Vosoughi E, Kiafar B, Nahidi Y, Momenzadeh A, Taheri AR. Efficacy of 
intralesional amphotericin B for the treatment of cutaneous leishmaniasis. Indian Journal 
of Dermatology. 2014;59:631-636. DOI: 10.4103/0019-5154.143571
Nanomedicines for Cutaneous Leishmaniasis
http://dx.doi.org/10.5772/intechopen.75750
197

